Key facts
- Notable investors include Dalton Venture, National Innovation Center for Advanced Medical Devices, Jenkem Technology, Triwise Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ruitong Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruitong Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruitong Bio
Developer and provider of ophthalmic degradable long-acting sustained-release technology designed to address the challenge of frequent eye drop administration. The company offers advanced drug delivery systems, enabling medical and veterinary users with long-duration release solutions for ocular care.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Ruitong Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruitong Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruitong Bio in its N-PORT filings yet. We sweep new filings monthly.